GRADE guidelines: 6. Rating the quality of evidence-imprecision

作者: Gordon H. Guyatt , Andrew D. Oxman , Regina Kunz , Jan Brozek , Pablo Alonso-Coello

DOI: 10.1016/J.JCLINEPI.2011.01.012

关键词:

摘要: GRADE suggests that examination of 95% confidence intervals (CIs) provides the optimal primary approach to decisions regarding imprecision. For practice guidelines, rating down quality evidence (i.e., in estimates effect) is required if clinical action would differ upper versus lower boundary CI represented truth. An exception this rule occurs when an effect large, and consideration CIs alone a robust effect, but total sample size not large number events small. Under these circumstances, one should consider for To inform decision, can calculate patients adequately powered individual trial (termed "optimal information size" [OIS]). continuous variables, we suggest similar process, initially considering limits CI, subsequently calculating OIS. Systematic reviews require somewhat different approach. If excludes relative risk (RR) 1.0, or exceeds OIS criterion, precision adequate. includes appreciable benefit harm (we RR under 0.75 over 1.25 as rough guide) imprecision may be appropriate even criteria are met.

参考文章(29)
Hussam Abuissa, Philip G. Jones, Steven P. Marso, James H. O’Keefe, Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. Journal of the American College of Cardiology. ,vol. 46, pp. 821- 826 ,(2005) , 10.1016/J.JACC.2005.05.051
R Collins, R Peto, M Flather, S Parish, P Sleight, M Conway, A Pipilis, C Baigent, D Barnett, JP Boissel, A Budaj, J Cairns, L Ceremuzynski, AF Cohen, Gui De Backer, R Diaz, F Dienstl, P Dove, MG Franzosi, M Genoni, DA Halon, J Heikkila, C Hennekens, J Horgan, D Hunt, R Kala, N Karatzas, A Keech, M Keltai, J Kjekshus, M Kornitzer, R Koster, P Landless, P Lechleitner, A Leizorovicz, BS Lewis, L Lundkvist, S Macmahon, A Maggioni, R Malacrida, T Meyer, T Moccetti, D Ocallaghan, E Paolasso, LS Piegas, A Reikvam, P Ridker, T Ryan, R Schroder, R Seabragomes, JEMR Sousa, G Tognoni, A Turpie, V Valentin, J Varigos, H White, L Wilhelmsen, K Woods, S Yusuf, A Piombo, LA Guzman, DC Montenegro, G Irusta, RA Schneider, C Cuneo, BH Chamorro, GE Espinosa, M Moreno, MM Rios, R Doll, K Fox, D Julian, P Meier, E Sandoya, JE Perez, None, ISIS-4 - A randomised factorial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58.050 patient with suspected acute myocardial-infarction. The Lancet. ,vol. 345, pp. 669- 685 ,(1995)
C. I. G. A. Reviewers, C. I. G. A. Reviewers, Cochrane Injuries Group Albumin ReviewersWhy albumin may not work BMJ. ,vol. 317, pp. 235- 240 ,(1998) , 10.1136/BMJ.317.7153.235
Berkeley N Limketkai, Anthony K Akobeng, Morris Gordon, Akinlolu Adedayo Adepoju, Probiotics for induction of remission in Crohn's disease Cochrane Database of Systematic Reviews. ,vol. 7, ,(2008) , 10.1002/14651858.CD006634.PUB3
Anat Gafter-Gvili, Abigail Fraser, Mical Paul, Leonard Leibovici, Meta-Analysis: Antibiotic Prophylaxis Reduces Mortality in Neutropenic Patients Annals of Internal Medicine. ,vol. 142, pp. 979- 995 ,(2005) , 10.7326/0003-4819-142-12_PART_1-200506210-00008
Thomas A. Trikalinos, Rachel Churchill, Marica Ferri, Stefan Leucht, Arja Tuunainen, Kristian Wahlbeck, John P.A. Ioannidis, Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time Journal of Clinical Epidemiology. ,vol. 57, pp. 1124- 1130 ,(2004) , 10.1016/J.JCLINEPI.2004.02.018
Salim Yusuf, Stephen Macmahon, Rory Collins, Richard Peto, EFFECT OF INTRAVENOUS NITRATES ON MORTALITY IN ACUTE MYOCARDIAL INFARCTION: AN OVERVIEW OF THE RANDOMISED TRIALS The Lancet. ,vol. 1, pp. 1088- 1092 ,(1988) , 10.1016/S0140-6736(88)91906-X